혈액투석 및 복막투석 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 제품 유형별, 용도별, 지역별 및 부문별 예측(2026-2033년)

Hemodialysis And Peritoneal Dialysis Market Summary

The global hemodialysis and peritoneal dialysis market size was estimated at USD 119.49 billion in 2025 and is projected to reach USD 250.38 billion by 2033, growing at a CAGR of 9.84% from 2026 to 2033. The demand for hemodialysis and peritoneal dialysis is driven by several factors, including the rising incidence of acute kidney injury, the scarcity of organ donors, the risks associated with transplants, technological advancements, and initiatives by leading players to introduce advanced products and services.

Any condition with reduced kidney function leads to chronic kidney disease, which may develop into End-Stage Renal Disease (ESRD) over a period. An increase in the prevalence of CKD is expected to boost demand for dialysis products. The rising prevalence of chronic kidney disease is becoming a major global health concern, significantly contributing to the growth of the hemodialysis and peritoneal dialysis market. CKD prevalence is expanding due to the rapid increase in lifestyle-related disorders such as diabetes, hypertension, and obesity, which are the leading causes of kidney damage. Moreover, CKD often progresses silently with minimal symptoms in its early stages, leading to late diagnosis and a higher likelihood of patients advancing to end-stage renal disease (ESRD), where dialysis becomes unavoidable. Improved screening programs and greater awareness are now identifying more cases, thereby expanding the pool of diagnosed patients. Environmental factors, including exposure to toxins and poor water quality in certain regions, are also contributing to the increase in CKD cases.

The growing burden of lifestyle-related diseases is a major factor accelerating the hemodialysis and peritoneal dialysis market, as these conditions are closely linked to kidney damage and eventual renal failure. Diseases such as Diabetes Mellitus and Hypertension are among the leading causes of chronic kidney disease, as prolonged high blood sugar levels and elevated blood pressure gradually impair kidney function over time. The increasing prevalence of obesity, physical inactivity, unhealthy diets, and smoking further exacerbates the risk of kidney complications, leading to a steady rise in CKD cases globally. According to the International Diabetes Federation in 2024, the global burden of Diabetes Mellitus is rapidly increasing, with approximately 589 million adults currently affected, a figure projected to reach 853 million by 2050, and notably, over 4 in 5 (81%) of these individuals residing in low- and middle-income countries.

As more patients with these lifestyle-related conditions progress to advanced stages of kidney disease, the demand for renal replacement therapies such as hemodialysis and peritoneal dialysis increases significantly. In addition, the earlier onset of these diseases in younger populations extends the duration of dialysis dependency, thereby increasing long-term treatment demand. This growing patient pool is driving the expansion of dialysis centers, greater adoption of home-based peritoneal dialysis, and increased use of dialysis consumables and equipment.

The hemodialysis and peritoneal dialysis market is growing due to continuous technological advancements in dialysis equipment, which are improving treatment efficiency, patient comfort, and clinical outcomes. Innovations such as high-flux dialyzers, portable and wearable hemodialysis machines, and automated peritoneal dialysis (APD) systems are making dialysis more convenient and accessible, especially for home-based care. Advanced monitoring features, real-time data tracking, and integration with digital health platforms enable better patient management and reduce complications associated with long-term dialysis. For instance, in 2025, Fresenius Medical Care AG, a leading provider of renal care products and services, is showcasing new research highlighting that hemodiafiltration (HDF) is linked to improved patient outcomes. The company is also emphasizing the role of artificial intelligence (AI) innovations in helping clinicians manage patients more effectively and in a data-driven way.

In addition, the development of biocompatible materials and infection-resistant catheters is enhancing patient safety and reducing the risk of adverse events. These technological improvements are encouraging higher adoption of both hemodialysis and peritoneal dialysis, supporting the shift toward home care settings, and prompting healthcare providers to upgrade existing infrastructure, thereby significantly contributing to market growth.

Global Hemodialysis And Peritoneal Dialysis Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends across sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hemodialysis and peritoneal dialysis market report based on type, product, end use, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Hemodialysis
  • Conventional hemodialysis
  • Short daily hemodialysis
  • Nocturnal hemodialysis
• Peritoneal Dialysis
  • Continuous Ambulatory Peritoneal Dialysis (CAPD)
  • Automated Peritoneal Dialysis (APD)
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Device
  • Machine
  • Dialyzer
  • Water treatment system
  • Others
• Consumables
  • Bloodline
  • Concentrates
  • Catheters
  • Others
• Service
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Home-Based
• Hospital-Based
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Type
  • 1.1.2. Product
  • 1.1.3. End-useEnd use
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
    • 1.3.5.1. Data for primary interviews in North America
    • 1.3.5.2. Data for primary interviews in Europe
    • 1.3.5.3. Data for primary interviews in Asia Pacific
    • 1.3.5.4. Data for primary interviews in Latin America
    • 1.3.5.5. Data for Primary interviews in MEA
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Product outlook
  • 2.2.3. End-use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Hemodialysis And Peritoneal Dialysis Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Industry Value Chain Analysis
  • 3.3.1. Reimbursement framework
• 3.4. Market Dynamics
  • 3.4.1. Market driver analysis
    • 3.4.1.1. Increasing prevalence of acute kidney injury (AKI) and associated chronic kidney diseases
    • 3.4.1.2. Increasing incidence and prevalence of ESRD
    • 3.4.1.3. Introduction to technologically advanced products
    • 3.4.1.4. Growing geriatric population
    • 3.4.1.5. Increase in number of diabetes patient
  • 3.4.2. Market restraint analysis
    • 3.4.2.1. Risk and complications associated with dialysis
    • 3.4.2.2. Issues with product approval & commercialization
  • 3.4.3. Market oppurtunity analysis
    • 3.4.3.1. Expansion of home hemodialysis (HHD) programs
    • 3.4.3.2. Increasing healthcare investments in emerging economies
    • 3.4.3.3. Rising adoption of biocompatible and high-flux dialyzers
    • 3.4.3.4. Growing preference for home-based peritoneal dialysis
    • 3.4.3.5. Increasing government initiatives and reimbursement support for renal care
  • 3.4.4. Market challnge analysis
    • 3.4.4.1. Limited patient awareness and acceptance of peritoneal dialysis in some regions
    • 3.4.4.2. Shortage of skilled nephrologists and trained dialysis technicians
• 3.5. Hemodialysis And Peritoneal Dialysis Market Analysis Tools
  • 3.5.1. Industry Analysis - Porter's
    • 3.5.1.1. Supplier power
    • 3.5.1.2. Buyer power
    • 3.5.1.3. Substitution threat
    • 3.5.1.4. Threat of new entrant
    • 3.5.1.5. Competitive rivalry
  • 3.5.2. PESTEL Analysis
    • 3.5.2.1. Political landscape
    • 3.5.2.2. Technological landscape
    • 3.5.2.3. Economic landscape

Chapter 4. Hemodialysis And Peritoneal Dialysis Market: Type Estimates & Trend Analysis

• 4.1. Definitions and Scope
• 4.2. Type Market Share, 2025 & 2033
• 4.3. Segment Dashboard
• 4.4. Hemodialysis And Peritoneal Dialysis Market by Type Outlook
• 4.5. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 4.5.1. Hemodialysis
    • 4.5.1.1. Hemodialysis market estimates and forecast 2021 to 2033 (USD Million)
    • 4.5.1.2. Conventional
      • 4.5.1.2.1. Conventional market estimates and forecast 2021 to 2033 (USD Million)
    • 4.5.1.3. Short Daily Hemodialysis
      • 4.5.1.3.1. Short daily hemodialysis market estimates and forecast 2021 to 2033 (USD Million)
    • 4.5.1.4. Nocturnal Hemodialysis
      • 4.5.1.4.1. Nocturnal hemodialysis market estimates and forecast 2021 to 2033 (USD Million)
  • 4.5.2. Peritoneal Dialysis
    • 4.5.2.1. Peritoneal dialysis market estimates and forecast 2021 to 2033 (USD Million)
    • 4.5.2.2. Continuous Ambulatory Peritoneal Dialysis (CAPD)
      • 4.5.2.2.1. Continuous ambulatory peritoneal dialysis (CAPD) market estimates and forecast 2021 to 2033 (USD Million)
    • 4.5.2.3. Automated Peritoneal Dialysis (APD)
      • 4.5.2.3.1. Automated peritoneal dialysis (APD) market estimates and forecast 2021 to 2033 (USD Million)

Chapter 5. Hemodialysis And Peritoneal Dialysis Market: Product Estimates & Trend Analysis

• 5.1. Definitions and Scope
• 5.2. Product Market Share, 2025 & 2033
• 5.3. Segment Dashboard
• 5.4. Hemodialysis And Peritoneal Dialysis Market by Product Outlook
• 5.5. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5.1. Device
    • 5.5.1.1. Device market estimates and forecast 2021 to 2033 (USD Million)
    • 5.5.1.2. Machine
      • 5.5.1.2.1. Machine market estimates and forecast 2021 to 2033 (USD Million)
    • 5.5.1.3. Dialyzers
      • 5.5.1.3.1. Dialyzers market estimates and forecast 2021 to 2033 (USD Million)
    • 5.5.1.4. Water Treatment System
      • 5.5.1.4.1. Water treatment system market estimates and forecast 2021 to 2033 (USD Million)
    • 5.5.1.5. Others
      • 5.5.1.5.1. Others market estimates and forecast 2021 to 2033 (USD Million)
  • 5.5.2. Consumables
    • 5.5.2.1. Consumables market estimates and forecast 2021 to 2033 (USD Million)
    • 5.5.2.2. Bloodlines
      • 5.5.2.2.1. Bloodlines market estimates and forecast 2021 to 2033 (USD Million)
    • 5.5.2.3. Concentrates
      • 5.5.2.3.1. Concentrates market estimates and forecast 2021 to 2033 (USD Million)
    • 5.5.2.4. Catheters
      • 5.5.2.4.1. Catheters market estimates and forecast 2021 to 2033 (USD Million)
    • 5.5.2.5. Others
      • 5.5.2.5.1. Others market estimates and forecast 2021 to 2033 (USD Million)
  • 5.5.3. Service
    • 5.5.3.1. Service market estimates and forecast 2021 to 2033 (USD Million)

Chapter 6. Hemodialysis And Peritoneal Dialysis Market: End-use Estimates & Trend Analysis

• 6.1. Definitions and Scope
• 6.2. End-use Market Share, 2025 & 2033
• 6.3. Segment Dashboard
• 6.4. Hemodialysis And Peritoneal Dialysis Market by End-use Outlook
• 6.5. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.5.1. Home-Based
    • 6.5.1.1. Home-based market estimates and forecast 2021 to 2033 (USD Million)
  • 6.5.2. Hospital-Based
    • 6.5.2.1. Hospital-based market estimates and forecast 2021 to 2033 (USD Million)

Chapter 7. Hemodialysis And Peritoneal Dialysis Market: Regional Estimates & Trend Analysis, by Type, Product, and End-use

• 7.1. Regional market share analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Regional Market Share and Leading Players, 2025
• 7.5. Market Product, & Forecasts, and Trend Analysis, 2021 to 2033:
• 7.6. North America
  • 7.6.1. Market estimates and forecast, 2021 - 2033 (Revenue, USD Million)
  • 7.6.2. U.S.
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. U.S. market estimates and forecasts, 2021 - 2033
  • 7.6.3. Canada
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. Canada market estimates and forecasts, 2021 - 2033
  • 7.6.4. Mexico
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. Regulatory framework
    • 7.6.4.4. Reimbursement scenario
    • 7.6.4.5. Mexico market estimates and forecasts, 2021 - 2033
• 7.7. Europe
  • 7.7.1. UK
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Competitive scenario
    • 7.7.1.3. Regulatory framework
    • 7.7.1.4. Reimbursement scenario
    • 7.7.1.5. UK market estimates and forecasts, 2021 - 2033
  • 7.7.2. Germany
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. Germany market estimates and forecasts, 2021 - 2033
  • 7.7.3. France
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. France market estimates and forecasts, 2021 - 2033
  • 7.7.4. Italy
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. Italy market estimates and forecasts, 2021 - 2033
  • 7.7.5. Spain
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Competitive scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Reimbursement scenario
    • 7.7.5.5. Spain market estimates and forecasts, 2021 - 2033
  • 7.7.6. Denmark
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Competitive scenario
    • 7.7.6.3. Regulatory framework
    • 7.7.6.4. Reimbursement scenario
    • 7.7.6.5. Denmark market estimates and forecasts, 2021 - 2033
  • 7.7.7. Sweden
    • 7.7.7.1. Key country dynamics
    • 7.7.7.2. Competitive scenario
    • 7.7.7.3. Regulatory framework
    • 7.7.7.4. Reimbursement scenario
    • 7.7.7.5. Sweden market estimates and forecasts, 2021 - 2033
  • 7.7.8. Norway
    • 7.7.8.1. Key country dynamics
    • 7.7.8.2. Competitive scenario
    • 7.7.8.3. Regulatory framework
    • 7.7.8.4. Reimbursement scenario
    • 7.7.8.5. Norway market estimates and forecasts, 2021 - 2033
• 7.8. Asia Pacific
  • 7.8.1. Japan
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Competitive scenario
    • 7.8.1.3. Regulatory framework
    • 7.8.1.4. Reimbursement scenario
    • 7.8.1.5. Japan market estimates and forecasts, 2021 - 2033
  • 7.8.2. India
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Competitive scenario
    • 7.8.2.3. Regulatory framework
    • 7.8.2.4. Reimbursement scenario
    • 7.8.2.5. India market estimates and forecasts, 2021 - 2033
  • 7.8.3. China
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Competitive scenario
    • 7.8.3.3. Regulatory framework
    • 7.8.3.4. Reimbursement scenario
    • 7.8.3.5. China market estimates and forecasts, 2021 - 2033
  • 7.8.4. South Korea
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Competitive scenario
    • 7.8.4.3. Regulatory framework
    • 7.8.4.4. Reimbursement scenario
    • 7.8.4.5. South Korea market estimates and forecasts, 2021 - 2033
  • 7.8.5. Australia
    • 7.8.5.1. Key country dynamics
    • 7.8.5.2. Competitive scenario
    • 7.8.5.3. Regulatory framework
    • 7.8.5.4. Reimbursement scenario
    • 7.8.5.5. Australia market estimates and forecasts, 2021 - 2033
  • 7.8.6. Thailand
    • 7.8.6.1. Key country dynamics
    • 7.8.6.2. Competitive scenario
    • 7.8.6.3. Regulatory framework
    • 7.8.6.4. Reimbursement scenario
    • 7.8.6.5. Thailand market estimates and forecasts, 2021 - 2033
• 7.9. Latin America
  • 7.9.1. Brazil
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Competitive scenario
    • 7.9.1.3. Regulatory framework
    • 7.9.1.4. Reimbursement scenario
    • 7.9.1.5. Brazil market estimates and forecasts, 2021 - 2033
  • 7.9.2. Argentina
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Competitive scenario
    • 7.9.2.3. Regulatory framework
    • 7.9.2.4. Reimbursement scenario
    • 7.9.2.5. Argentina market estimates and forecasts, 2021 - 2033
• 7.10. MEA
  • 7.10.1. South Africa
    • 7.10.1.1. Key country dynamics
    • 7.10.1.2. Competitive scenario
    • 7.10.1.3. Regulatory framework
    • 7.10.1.4. Reimbursement scenario
    • 7.10.1.5. South Africa market estimates and forecasts, 2021 - 2033
  • 7.10.2. Saudi Arabia
    • 7.10.2.1. Key country dynamics
    • 7.10.2.2. Competitive scenario
    • 7.10.2.3. Regulatory framework
    • 7.10.2.4. Reimbursement scenario
    • 7.10.2.5. Saudi Arabia market estimates and forecasts, 2021 - 2033
  • 7.10.3. UAE
    • 7.10.3.1. Key country dynamics
    • 7.10.3.2. Competitive scenario
    • 7.10.3.3. Regulatory framework
    • 7.10.3.4. Reimbursement scenario
    • 7.10.3.5. UAE market estimates and forecasts, 2021 - 2033
  • 7.10.4. Kuwait
    • 7.10.4.1. Key country dynamics
    • 7.10.4.2. Competitive scenario
    • 7.10.4.3. Regulatory framework
    • 7.10.4.4. Reimbursement scenario
    • 7.10.4.5. Kuwait market estimates and forecasts, 2021 - 2033

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
  • 8.2.1. Innovators
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2025
  • 8.3.4. BD
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Baxter
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. B. Braun SE
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Medtronic
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Fresenius Medical Care AG
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. DaVita
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Asahi Kasei Medical Co., Ltd.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Nipro Corp.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Nikkiso Co., Ltd.
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Cantel Medical
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. Diaverum (M42)
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Product benchmarking
    • 8.3.14.4. Strategic initiatives
  • 8.3.15. vivISOL
    • 8.3.15.1. Company overview
    • 8.3.15.2. Financial performance
    • 8.3.15.3. Product benchmarking
    • 8.3.15.4. Strategic initiatives